caa a22 4500 477071872 CHVBK 20180405111428.0 cr unu---uuuuu 170330e19960301xx s 000 0 eng 10.1007/BF00051132 doi (NATIONALLICENCE)springer-10.1007/BF00051132 Effects of beta-blockers on HMG CoA reductase and LDL receptor activity in cultured human skin fibroblasts [Elektronische Daten] [Hiroshi Yoshida, Michio Suzukawa, Toshitsugu Ishikawa, Hideki Shige, Eisuke Nishio, Hiroshi Hosoai, Makoto Ayaori, Haruo Nakamura] Summary: Previous reports, based on clinical trials and animal experiments, suggest that beta-blockers may be useful in the prevention of atherosclerosis. Betaxolol, a new beta1-selective blocker, was shown to decrease plasma total and LDL cholesterol levels or to have no adverse effect on those [1-4]. While many reports deal with the metabolism of triglyceride and high density lipoprotein, fewer publications about cholesterol metabolism are currently available. To clarify the mechanism by which beta-blockers affect lipid metabolism, we examined the effects of beta-blockers on HMG CoA reductase and LDL receptor activity in cultured human skin fibroblasts. L-propranolol, a nonselective betablocker, increased HMG CoA reductase activity and decreased LDL receptor activity. However, d-propranolol had no major effects on HMG CoA reductase activity. These results suggest that beta-blockers act on HMG CoA reductase through the beta receptors. Beta1-blocking action should decrease HMG CoA reductase activity and increase LDL receptor activity. In fact, betaxolol, a beta1-selective blocker, decreased HMG CoA reductase activity and increased LDL receptor activity, but metoprolol had no major effect. We speculate that the discrepancy between betaxolol and metoprolol in the effect on HMG CoA reductase and the LDL receptor might be due to the difference of the extent of beta1-selectivity. We conclude that beta1-selective blockers are antihypertensive agents potentially valuable in the prevention of atherosclerosis. Kluwer Academic Publishers, 1996 HMG CoA reductase nationallicence LDL receptor nationallicence beta-blocker nationallicence beta1-selectivity nationallicence human skin fibroblasts nationallicence Yoshida Hiroshi lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut Suzukawa Michio lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut Ishikawa Toshitsugu lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut Shige Hideki lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut Nishio Eisuke lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut Hosoai Hiroshi lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut Ayaori Makoto lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut Nakamura Haruo lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/1(1996-03-01), 67-74 0920-3206 10:1<67 1996 10 10557 https://doi.org/10.1007/BF00051132 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00051132 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yoshida Hiroshi lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut NATIONALLICENCE 700 1- Suzukawa Michio lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut NATIONALLICENCE 700 1- Ishikawa Toshitsugu lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut NATIONALLICENCE 700 1- Shige Hideki lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut NATIONALLICENCE 700 1- Nishio Eisuke lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut NATIONALLICENCE 700 1- Hosoai Hiroshi lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut NATIONALLICENCE 700 1- Ayaori Makoto lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut NATIONALLICENCE 700 1- Nakamura Haruo lst Department of Internal Medicine, National Defense Medical College, Saitma, Japan aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/1(1996-03-01), 67-74 0920-3206 10:1<67 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer